LUNAI BIOWORKS INC (LNAI) Stock Price & Overview
NASDAQ:LNAI • US29350E2037
Current stock price
The current stock price of LNAI is 0.3086 USD. Today LNAI is down by -0.48%. In the past month the price decreased by -25.24%.
LNAI Key Statistics
- Market Cap
- 11.193M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -7.14
- Dividend Yield
- N/A
LNAI Stock Performance
LNAI Stock Chart
LNAI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to LNAI.
LNAI Earnings
LNAI Forecast & Estimates
LNAI Groups
Sector & Classification
LNAI Financial Highlights
Over the last trailing twelve months LNAI reported a non-GAAP Earnings per Share(EPS) of -7.14. The EPS decreased by -50.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1882.9% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
LNAI Ownership
LNAI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.31 | 349.118B | ||
| AMGN | AMGEN INC | 14.9 | 183.592B | ||
| GILD | GILEAD SCIENCES INC | 14.45 | 158.566B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.87 | 108.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.88 | 78.702B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.2 | 41.165B | ||
| INSM | INSMED INC | N/A | 29.351B | ||
| NTRA | NATERA INC | N/A | 28.968B | ||
| BIIB | BIOGEN INC | 11.21 | 26.515B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.093B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.4 | 24.851B | ||
| MRNA | MODERNA INC | N/A | 19.314B | ||
| INCY | INCYTE CORP | 12.37 | 19.048B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LNAI
Company Profile
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 29 full-time employees. The company went IPO on 2014-11-18. The company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. Its segments include RENB, BioSymetrics and RENC. The RENB segment is engaged in developing new immunotherapies to combat cancer. BioSymetrics is engaged in integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine. RENC is developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform.
Company Info
IPO: 2014-11-18
LUNAI BIOWORKS INC
2080 Century Park East, Suite 906
Los Angeles CALIFORNIA US
Employees: 29
Phone: 18885282677
LUNAI BIOWORKS INC / LNAI FAQ
What does LNAI do?
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 29 full-time employees. The company went IPO on 2014-11-18. The company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. Its segments include RENB, BioSymetrics and RENC. The RENB segment is engaged in developing new immunotherapies to combat cancer. BioSymetrics is engaged in integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine. RENC is developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform.
What is the current price of LNAI stock?
The current stock price of LNAI is 0.3086 USD. The price decreased by -0.48% in the last trading session.
Does LNAI stock pay dividends?
LNAI does not pay a dividend.
How is the ChartMill rating for LUNAI BIOWORKS INC?
LNAI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is LNAI stock listed?
LNAI stock is listed on the Nasdaq exchange.
What is the market capitalization of LNAI stock?
LUNAI BIOWORKS INC (LNAI) has a market capitalization of 11.19M USD. This makes LNAI a Nano Cap stock.